Novavax (NVAX 9.11%) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported lower-than-expected earnings.The vaccine maker has struggled to win over the investment community after entering the coronavirus vaccine market late with its initial vaccine -- and commercializing its updated vaccine after rivals this past fall.The initial late entry meant Novavax missed out on the biggest revenue oppor ...

Since 2021, shares of Novavax (NVAX 12.02%) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the past few years. The price drop was justified largely because the company's fate was uncertain. There were question marks relating to its growth and a canceled purchase agreement.The good news is that one of those issues recently reached a positive resolution. Is that enough to make this beaten-down stock worth tak ...

GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, March 6, 2024 Time: 1:30 – 2:00 p.m. Eastern Standard Time (EST) Location: Boston Marriott Copley Place in Boston, Massachusetts Moderator: Brendan Smith, Ph.D., Vice President, Biotechnology ...

Novavax, Inc. (NVAX) reported a fourth-quarter 2023 loss of $1.44 cents per share, much wider than the Zacks Consensus Estimate of a loss of 49 cents. In the year-ago quarter, the company reported a loss of $2.28 per share.Revenues in the quarter amounted to $291.3 million, also missing the Zacks Consensus Estimate of $334.0 million. The top line declined 18.5% on a year-over-year basis.Quarter in DetailIn the reported quarter, the company recorded $251.4 million in product sales, reflecting a decrease of 1 ...

© 2024 NOVAVAX. All rights reserved. 1 | --- | --- | --- | --- | |--------------------------------------------|-------|-------|-------| | | | | | | | | | | | Fourth quarter & full | | | | | | | | | | | | | | | year 2023 financial results & operational | | | | | highlights | | | | | Nasdaq: NVAX \| February 28th, 2024 | | | | © 2024 NOVAVAX. All rights reserved. Q4 and FY 2023 Earnings call Erika Schultz Senior Director, Investor Relations John C. Jacobs President and Chief Executive Officer NovavaxTM (and a ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

For the quarter ended December 2023, Novavax (NVAX) reported revenue of $291.34 million, down 18.5% over the same period last year. EPS came in at -$1.44, compared to -$2.28 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $334.46 million, representing a surprise of -12.89%. The company delivered an EPS surprise of -193.88%, with the consensus EPS estimate being -$0.49.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Novavax Inc (NASDAQ:NVAX) missed top- and bottom-line estimates for the fourth quarter. The company noted its plans to cut costs, and still narrowed losses from the fourth quarter despite slowing Covid-19 vaccine demand. NVAX is down 26.3% to trade at $4.43 at last check.The shares have struggled to stay above penny stock territory, while their 200-day moving average has acted as long-term pressure. If these losses hold, NVAX could mark its worst daily percentage loss since December 2022. In the past 12 mon ...

Novavax (NASDAQ:NVAX) stock is falling hard on Wednesday as investors react to the vaccine company’s earnings report for the fourth quarter of 2024.Let’s dig into everything that has investors in NVAX stock disappointed today below!NVAX Earnings Hit StockNovavax reported earnings per share of -$1.44 during the quarter.That’s worse than the -35 cents per share that Wall Street was expecting.However, it is better than the -$2.28 from the same time last year.Revenue of $291.34 million also failed to meet the a ...

Novavax (NVAX) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $2.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -193.88%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.82 per share when it actually produced a loss of $1.26, delivering a surprise of 30.77%.Over the last four quarters, the company has surpasse ...